About Optimum Therapeutics
Optimum Therapeutics is a Technology company based in San Diego (United States) founded in 2008. Tumor-selective therapeutics are discovered and developed for solid tumors. It operates in the Technology and Healthcare sectors. Its Indian entity Optimum Therapeutics Private Limited reported revenue of ₹23.73 Cr. Its focus areas include High Tech, Nanotechnology, Nanoenabled Products and Life Science. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Optimum Therapeutics discovers and develops therapeutics for the treatment of solid tumors by improving nanomedicine delivery and transport. The company has been awarded 9 grants from SBIR for a total value of 4.75M. Its lead candidate for bladder cancer is in Phase III. The next lead candidate is a Noncytotoxic chemosensitizer, in Phase II trials. It is also developing a drug candidate for Peritoneal Cancer, which is currently in preclinical stages.
- Headquarters San Diego, United States
- SectorsTechnologyHealthcare
- Email••••••••
- Website optimumtx.com
- Social LinkedIn
- Legal Name Optimum Therapeutics Private Limited
- Date of Incorporation 13 Dec, 2011
- Jurisdiction New Delhi, Delhi, India
- Indian entity revenue₹23.73 Cr
FY 2024 · +16% YoY
- Indian entity net profit₹1.74 Cr
FY 2024 · 7% margin
- Indian entity EBITDA₹3.32 Cr
FY 2024 · 14% margin
- Latest Funding Round$344.46K (USD), Grant
Sep 2012
- InvestorsNIH
& 1 more
Associated legal entities of Optimum Therapeutics
Optimum Therapeutics operates through Optimum Therapeutics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Optimum Therapeutics Private Limited CIN U85100DL2011PTC228675 | Active | 13 Dec 2011 | New Delhi, Delhi | ₹23.7 Cr | 2 | View details |
Funding Insights of Optimum Therapeutics
- Total Rounds 14
- Last Round Grant — $344,460
- First Round $615,979
(Sep 2007)
- Investors Count 2
Latest 10 of 14 funding rounds of Optimum Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2012 | $344,460 | Grant | – | – | |
| Apr 2012 | $1.37M | Grant | – | – | |
| Apr 2012 | $615,979 | Grant | – | – | |
| Apr 2012 | $1.92M | Grant | – | – | |
| Mar 2012 | $1.92M | Grant | – | – | |
| Sep 2011 | $1.83M | Grant | – | – | |
| Sep 2011 | $303,226 | Grant | – | – | |
| Sep 2011 | $2.44M | Grant | – | – | |
| Sep 2009 | $1.78M | Grant | – | – | |
| Sep 2009 | $400,000 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Optimum Therapeutics
Optimum Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Optimum Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Optimum Therapeutics Private Limited (Optimum Therapeutics)
Optimum Therapeutics Private Limited is the primary company behind Optimum Therapeutics. The board of Optimum Therapeutics Private Limited currently have 2 directors; the longest-serving is Sharmin Yaqin, appointed in 2011.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sharmin Yaqin DIN 01579448 | Director | 13 Dec 2011 | 14 yrs 10 mo | Optimum Therapeutics Private Limited |
| Jamal Anono Khan DIN 00329984 | Director | 13 Dec 2011 | 14 yrs 10 mo | Optimum Therapeutics Private Limited |
Financials of Optimum Therapeutics
Figures of Optimum Therapeutics Private Limited, the primary company behind Optimum Therapeutics, for FY 2024. Revenue was ₹23.73 Cr (+16% year on year). Net profit was ₹1.74 Cr (7% margin). EBITDA was ₹3.32 Cr (14% margin). Revenue has grown at a compounded annual rate of +15% over three years and +16% over five years.
- ₹23.73 CrRevenue · FY 2024 · +16% YoY
- ₹1.74 CrNet profit · 7% margin
- ₹3.32 CrEBITDA · 14% margin
- ₹1 LakhPaid-up capital
- +15%Revenue CAGR, 3 years
- +16%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Optimum Therapeutics Private Limited are on its company page.
Detailed financial statements for Optimum Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Optimum Therapeutics
3 dated milestones of Optimum Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round of $616K.
- Founded Optimum Therapeutics is founded.
- Funding Latest funding round, Grant, of $344K.
Competitors of Optimum Therapeutics
Optimum Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Optimum Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Nanotechnology
3 companies that operate in the same segment as Optimum Therapeutics (Nanotechnology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of technologies for analysis of genetic variation and function | 1993 | San Diego, California, United States | USD 28 M | USD 1.44 M | 29 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Aerogel-based thermal insulation solutions are provided for energy conservation. | 2001 | United States | USD 198.35 M | USD 271.1 M | 554 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Optimum Therapeutics
Optimum Therapeutics was founded in 2008.
Optimum Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
The primary company behind Optimum Therapeutics, Optimum Therapeutics Private Limited, reported revenue of ₹23.73 Cr for FY 2024, up 16% year on year.
Optimum Therapeutics discovers and develops therapeutics for the treatment of solid tumors by improving nanomedicine delivery and transport. The company has been awarded 9 grants from SBIR for a total value of 4.75M. Its lead candidate for bladder cancer is in Phase III. The next lead candidate is a Noncytotoxic chemosensitizer, in Phase II trials. It is also developing a drug candidate for Peritoneal Cancer, which is currently in preclinical stages.
Optimum Therapeutics's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Optimum Therapeutics operates through Optimum Therapeutics Private Limited.
The legal entities of Optimum Therapeutics currently have 2 directors, including Sharmin Yaqin, Jamal Anono Khan.